Loading
A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) is a phase 3 interventional study registered as NCT06312137 by Merck Sharp & Dohme LLC, with 780 participants planned, started 2024-04-03 and due to reach its primary completion in 2034-02-21. Interventions recorded: Sacituzumab tirumotecan, Pembrolizumab, Cisplatin, Pemetrexed, Gemcitabine. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Carboplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Merck & Co. (MSD), Gemcitabine.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), Cisplatin, Carboplatin.
Shares Pemetrexed, Merck & Co. (MSD), Cisplatin, Carboplatin.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Gemcitabine.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Cisplatin.
Shares Pemetrexed, Merck & Co. (MSD), Cisplatin, Carboplatin.